patent

News

Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

News

SCOTUS won’t hear ‘skinny label’ lawsuit

The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t

News

Relief for Amgen as it wins Otezla patent appeal

Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin

R&D

Competition is on the horizon for costly narcolepsy treatmen...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment.

News

EU says Teva blocked generics to MS drug Copaxone

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it

News

Supreme court throws Novartis a lifeline for Gilenya defense

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.

Novartis will appeal Entresto patent setback

SCOTUS won’t hear ‘skinny label’ lawsuit

Relief for Amgen as it wins Otezla patent appeal

Competition is on the horizon for costly narcolepsy treatmen...

EU says Teva blocked generics to MS drug Copaxone

Supreme court throws Novartis a lifeline for Gilenya defense

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

patent

Editor's Picks